Study On Anti-atherosclerosis With Micro-powder Of Lipid-reducing Hongqu And Intervention In The Atherosclerosis Of Apolipoprotein E Gene Knockout Mice

Objective: Compared with Xuezhikang and Lovastatin, to observe the therapeutic effect and security on treatment of hyperlipidemia and carotid atherosclerosis with different doses of micro-powder of lipid-reducing Hongqu(MLH); and to observe its effect on blood lipids, aorta atherosclerosis and plaque stability of apolipoprotein E gene knockout mice.Methods: 1. Clinical study: 100 patients with hyperlipidemia were divided into 5 groups: Group A(MLH of 1/2 dose group), Group B(MLH of full dose group), Group C(rough-powder of lipid-reducing Hongqu group), Group D(Xuezhikang group) and Group E(Lovastatin group). To observe the changes of clinical symptoms, blood lipid, apolipoprotein, anti-oxidation and endothelial function after 50 days of treatment. Another 120 patients with hyperlipidemia and carotid atherosclerosis were divided into 6 groups, above mentioned A-E groups and F group(blank group), the course of treatment was 6 months. To observe the effect on clinical symptoms, blood lipid, carotid and femoral artery atherosclerosis. 2. Experimental study: MLH, Xuezhikang and Lovastatin were administered on 6-week-old ApoE(-/-) mice. After 34 weeks, to observe the effect on TC, TG, LDL-C, HDL-C, and take aorta to take pathomorphology observation and assay the expression of NF-κB mRNA, MMP-9mRNA.Results: 1. After 50 days of treatment, clinical symptoms improved in all groups, and the significant effective rate of A and B groups were superior to those of group C,D and E.TC and ApoB100/ApoAI reduced in all groups, TG reduce in group A and E, ApoAIelevated in group A, B, C and D. Lp(a)reduce in group A, B and D.2. After 50 days of treatment, NO elevated, ET/NO,ET/CGRP reduced in all groups, ET reduce in group A, B, D and E; FMD improve in group A, D and E; SOD elevated and ox-LDL reduced in all groups, MDA reduced in group A, B, C and D.3. After 6 months of treatment on patients with hyperlipidemia and carotid atherosclerosis, clinical symptoms improved in all groups and there was no difference among all treatment groups. TC reduced in all groups and TG reduced in group A, B, D and E. IMT of carotid and femoral artery reduced in all groups, and Crouse integral of carotid atherosclerotic plaque reduced in all treatment groups and was superior to blank group.4. MHL could reduce blood lipid, anti-proliferation of SMC, anti-atherosclerosis, and stabilize atherosclerotic plaque, and it could reduce expression of NF-κBmRNA and MMP-9 mRNA in aorta.Conclusion: MHL has an exact effect of reducing blood lipid, anti-atherosclerosis and stabilize atherosclerotic plaque, deserved to be applied and spread.